GlassScriptPhysician profile
Lori B Ponder
NPI 1235110263
$2,292.95
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $896 · 2022: $501 · 2023: $881 · 2024: $14.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.34 | 2021-2023 | |
| Pfizer INC. | $165.21 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.37 | 2021-2022 | |
| Lilly USA, LLC | $140.60 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $127.38 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $108.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $82.04 | 2021 | |
| Novo Nordisk INC | $60.76 | 2023 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $53.44 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $52.00 | 2021-2023 | |
| Horizon Therapeutics Plc | $48.21 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.66 | 2021 | |
| Dexcom, INC. | $38.55 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $38.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $38.46 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.54 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $29.17 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $26.61 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $21.16 | 2023 | Coolseal Generator |
| Bausch Health US, LLC | $20.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.13 | 2023 | |
| Merck Sharp & Dohme LLC | $14.45 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $13.67 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.92 | 2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $12.80 | 2023 | |
| Esperion Therapeutics, INC. | $12.79 | 2021 | |
| Genentech USA, INC. | $8.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ponder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.